Metadoxil® is a drug used to treat chronic and acute alcohol intoxication. It has a hepatoprotection, detoxification andanti-alcohol effect.
In clinical studies, metadoxine has been reported to reduce half-life of ethanol in healthy volunteers and in acutely intoxicated patients; to accelerate the metabolism of alcohol and acetaldehyde into less toxic higher ketones and to improve their urinary clearance; to restore laboratory variables such as alcohol, ammonia, γ-GT, and alanine aminotransferase; and to improve clinical symptoms of alcohol intoxication, including psychomotor agitation, depression, aggressiveness, and equilibrium disorders.There is also evidence that metadoxine has an effect on reducing craving for alcohol. Data from clinical studies also support an effect of metadoxine on reducing indices of liver cell necrosis and fat accumulation in alcoholic fatty liver.
Indications for use
- Complex therapy of liver diseases, especially of alcohol etiology;
- Chronic alcoholism.
- Acute alcohol intoxication;
- Alcohol withdrawal syndrome.
Dosage and administration
The drug is prescribed as part of the complex therapy of liver diseases and chronic alcoholism in the amount of 500 mg (1 tablet) 2 times a day 15-30 minutes before meals. The dose can be increased to 1500 mg (3 tablets) per day if necessary. The course of treatment is at least 90 days.
In acute alcohol intoxication, the drug is administered i/m in the amount of 300-600 mg (5-10 ml) or i/v in the amount of 300-900 mg (5-15 ml) depending on the severity of intoxication. In case of the intravenous mode of administration, the desired dose of the drug is dissolved in 500 ml of saline or in a 5% glucose solution and is administered by drop infusion for 90 minutes.
In case of alcohol withdrawal syndrome the drug is administered i/v in the form of an infusion at a dose of 900 mg (15 ml) 1 time / during 4-7 days, depending on the patient's condition.
- Pregnancy and lactation;
- Hypersensitivity to the drug components.
The drug should be prescribed with caution in case of Parkinson's disease if Levodopa is used at the same time, because metadoxine reduces the effectiveness of the latter.
Possible: allergic response. Bronchospasm may develop in patients with bronchial asthma (when using an injection). If side effects are manifested, it is recommended to cancel the drug and prescribe maintenance therapy.